ArticleBMC oral health2025
Awareness and Attitude Towards MRONJ Among Physicians Prescribing Antiresorptive Drugs: A Cross-Sectional Study.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From Prescription to Prevention: Patient Awareness, Risk Perceptions, and Predictors of Knowledge of Medication-Related Osteonecrosis of the Jaw.Journal of clinical medicine · 2026Article
- Medical practitioners' awareness and practices regarding bisphosphonate therapy and oral health risks: a Malaysian cross‑sectional study.BMC oral health · 2026Article
- Therapeutic potential of natural products from Traditional Chinese Medicine in the treatment of osteoporosis.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMRONJ (Medication-Related Osteonecrosis of the Jaw) refers to a condition characterized by osteonecrosis of the jawbone associated with the use of certain medications. One of the most common causes of MRONJ is bisphosphonates, which are frequently used today to treat osteoporosis, metabolic bone diseases, and the skeletal effects of malignancies.
objectiveThe aim of this study is to assess the awareness and approaches of medical doctors who prescribe bisphosphonate group drugs regarding MRONJ.
methodA total of 125 physicians specializing in the departments of oncology, orthopedics and traumatology, physical medicine and rehabilitation, and obstetrics and gynecology participated in our study. The participants completed questionnaire forms consisting of 15 questions related to MRONJ, and the results were analyzed.
resultsThe specialists who participated in the study were found to prescribe zoledronate and alendronate more frequently than other antiresorptive medications. Over the past year, when examining the frequency of encountering patients with MRONJ, 56% of physicians had not encountered any cases, while 44% had encountered between one and four cases. The group that most frequently requested consultations from physicians regarding bisphosphonates was identified as dentists, with a rate of 50.4%, followed by oral and maxillofacial surgeons at 36.8%. The specialists who participated in the study reported that when they encounter patients with osteonecrosis, 39.2% most frequently referred them to oral and maxillofacial surgery.
conclusionTo enhance awareness of MRONJ, a multidisciplinary approach should be adopted between medical and dental disciplines, and a well-coordinated consultation system should be established. This will ensure that patients undergo dental examinations and complete necessary interventional dental procedures before commencing antiresorptive drug therapy. Furthermore, implementing educational strategies such as academic publications, training seminars, and symposia is of great importance to increase the level of awareness on this issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.